[CAS NO. 302543-62-0] Rosiglitazone hydrochloride

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [302543-62-0]

Catalog

HY-17386A

Brand

MCE

CAS

302543-62-0

DESCRIPTION [302543-62-0]

Overview

MDL	-
Molecular Weight	393.89
Molecular Formula	C18H20ClN3O3S
SMILES	[H]Cl.O=C(N1)SC(CC2=CC=C(OCCN(C)C3=NC=CC=C3)C=C2)C1=O

For research use only. We do not sell to patients.

83 Publications Citing Use of MCE

Summary

Rosiglitazone (BRL 49653) hydrochloride is an orally active selective PPARγ agonist ( EC ₅₀ : 60 nM, K _d : 40 nM). Rosiglitazone hydrochloride is a TRPC5 activator ( EC ₅₀ : 30 μM) and TRPM3 inhibitor. Rosiglitazone hydrochloride can be used in the research of obesity and diabetes, senescence, ovarian cancer ^[1] ^[2] ^[4] ^[7] .

IC50 & Target

PPARγ

40 nM (Kd)

PPARγ

60 nM (EC ₅₀ )

TRPC5

30 μM (EC ₅₀ )

TRPM3

In Vitro

Rosiglitazone hydrochloride (0.1-10 μM, 72 h) results in pluripotent C3H10T1/2 stem cell differentiation to adipocytes ^[1] .
Rosiglitazone hydrochloride (1 μM, 24 h) activates PPARγ , which binds to NF-α1 promoter to activate gene transcription in neurons ^[3] .
Rosiglitazone hydrochloride (1 μM, 24 h) protects Neuro2A cells and hippocampal neurons against oxidative stress, and up-regulates BCL-2 expression in an NF-α1-dependent manner ^[3] .
Rosiglitazone hydrochloride (0.01-100 μM, 15 min) inhibits TRPM3 with IC ₅₀ values of 9.5 and 4.6 μM against nifedipine- and PregS-evoked activity respectively ^[4] .
Rosiglitazone hydrochloride (0.5-50 μM, 7 days) inhibits ovarian cancer cell proliferation ^[7] .
Rosiglitazone hydrochloride (5 μM, 7 days) suppresses Olaparib ( HY-10162 )‑induced alterations of cellular senescence and promotes apoptosis in A2780 and SKOV3 cells ^[7] .

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay ^[7]

Cell Line:	A2780 and SKOV3 cells
Concentration:	0.5-50 μM
Incubation Time:	1-7 days
Result:	Inhibited cell proliferation in a time‑dependent and concentration‑dependent manner.

Western Blot Analysis ^[3]

Cell Line:	Hippocampal neurons
Concentration:	1 μM
Incubation Time:	1 μM
Result:	Increased NF-α1 and BCL-2 protein level.

In Vivo

Rosiglitazone hydrochloride (oral administration, 5 mg/kg, daily for 8 weeks) decreases the serum glucose in diabetic rats ^[5] .
Rosiglitazone hydrochloride (intraperitoneal injection, 3 mg/kg/day) ameliorates airway inflammation induced by cigarette smoke via inhibiting the M1 macrophage polarization by activating PPARγ and RXRα in male Wistar rats ^[6] .
Rosiglitazone hydrochloride (intraperitoneal injection, 10 mg/kg, once every 2 days) inhibits subcutaneous ovarian cancer growth in A2780 and SKOV3 mouse subcutaneous xenograft models ^[7] .

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Streptozotocin (STZ)-induced diabetic rats ^[5]
Dosage:	5 mg/kg
Administration:	Oral administration, daily for 8 weeks.
Result:	Decreased IL-6, TNF-α, and VCAM-1 levels in diabetic group. Displayed lower levels of lipid peroxidation and NOx with an increase in aortic GSH and SOD levels compared to diabetic groups.

Animal Model:	Male Wistar rats ^[6]
Dosage:	3 mg/kg/day
Administration:	Intraperitoneal injection, twice a day, 6 days per week for 12 consecutive weeks
Result:	Ameliorated emphysema, elevated PEF, and higher level of total cells, neutrophils and cytokines (TNF-α and IL-1β) induced by cigarette smoke (CS). Inhibited CS-induced M1 macrophage polarization and decreased the ratio of M1/M2.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00636766	Aristotle University Of Thessaloniki	Carotid Atherosclerosis\|Stroke\|Type 2 Diabetes\|Metabolic Syndrome	September 2005	Not Applicable
NCT00143624	University of British Columbia	Atherosclerosis\|HIV Infections	June 2003	Not Applicable
NCT00483392	University Medical Centre Ljubljana	Insulin Resistance		Not Applicable
NCT00182052	Massachusetts General Hospital\|Dana-Farber Cancer Institute	Adenocarcinoma of the Prostate\|Prostate Cancer	September 2000	Phase 3
NCT00567593	James Lewis\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|University of Pennsylvania	Inflammatory Bowel Disease	October 2007	Phase 4
NCT00369174	National Cancer Institute (NCI)	Oral Leukoplakia	June 2006	Phase 2
NCT00746174	University of Texas Southwestern Medical Center\|GlaxoSmithKline	Insulin Sensitivity	February 2004	Phase 4
NCT01402076	Vanda Pharmaceuticals	Healthy Volunteers	August 2011	Phase 1
NCT00577590	Washington University School of Medicine	Diabetes Mellitus, Type II	October 2003	Not Applicable
NCT00084578	Fox Chase Cancer Center\|National Cancer Institute (NCI)	Bladder Cancer	March 2004	Not Applicable
NCT00489229	Universiti Sains Malaysia\|Ministry of Health, Malaysia	Diabetes\|Impaired Glucose Tolerance	October 2002	Phase 3
NCT00361868	Solvay Pharmaceuticals	Dyslipidemia\|Glucose Metabolism Disorder	June 2006	Phase 3
NCT01150981	University of Massachusetts, Worcester\|GlaxoSmithKline	Metabolic Syndrome\|Insulin Resistance	November 2006	Phase 2
NCT01287598	Bayer	Neoplasms	August 2, 2011	Phase 1
NCT00831129	University of Chicago\|GlaxoSmithKline	Pre-diabetes	September 2006	Phase 2\|Phase 3
NCT00370305	Charite University, Berlin, Germany	Metabolic Syndrome\|Impaired Glucose Tolerance	May 2004	Phase 2
NCT00501020	GlaxoSmithKline	Diabetes Mellitus, Type 2	June 5, 2001	Phase 4
NCT00733785	GlaxoSmithKline	Alzheimer´s Disease	August 13, 2008	Phase 1
NCT00193648	Northwell Health\|University of North Carolina\|The Cleveland Clinic	Focal Glomerulosclerosis	July 2005	Phase 1
NCT00242593	University of Washington\|National Institute on Aging (NIA)\|GlaxoSmithKline	Mild Cognitive Impairment	June 2006	Phase 2
NCT00964106	GlaxoSmithKline	Drug Interactions	August 26, 2009	Phase 1
NCT00169923	Leiden University Medical Center	Chronic Kidney Disease\|Inflammation	April 2007	Phase 2\|Phase 3
NCT00306644	GlaxoSmithKline	Diabetes Mellitus, Type 2	May 2002	Phase 4
NCT00006493	National Center for Research Resources (NCRR)	HIV Infections\|Hyperlipidemia		Phase 2
NCT00486187	Dr. Milan Gupta\|GlaxoSmithKline\|Canadian Collaborative Research Network	Type 2 Diabetes Mellitus	April 2006	Not Applicable
NCT01415128	VIVUS LLC	Erectile Dysfunction	April 2010	Phase 1
NCT00680745	AstraZeneca\|Bristol-Myers Squibb	Type 2 Diabetes	April 2008	Phase 3
NCT00549874	University of Michigan\|GlaxoSmithKline	Type 2 Diabetes	February 2002	Not Applicable
NCT00149383	Mahidol University\|McLaughlin-Rotman Center for Global Health, University of Toronto	Falciparum Malaria	December 2004	Phase 1\|Phase 2
NCT00225342	University of Glasgow\|GlaxoSmithKline	Angina Pectoris\|Diabetes Mellitus, Type 2		Phase 4
NCT04148183	J JESUS VENEGAS, MD\|Instituto Mexicano del Seguro Social\|National Council of Science and Technology, Mexico\|Universidad de Colima	Insulin Resistance	January 1, 2004	Phase 2\|Phase 3
NCT00225225	Stanford University\|GlaxoSmithKline	Diabetes Mellitus, Type 2	October 2002	Not Applicable
NCT00879970	GlaxoSmithKline\|Population Health Research Institute	Diabetes Mellitus, Type 2	May 2009	Phase 4
NCT01406704	Seoul St. Mary´s Hospital\|GlaxoSmithKline	NASH (Non-alcoholic Steato-hepatitis)	January 2004	Phase 4
NCT00194896	University of Washington\|Seattle Institute for Biomedical and Clinical Research\|GlaxoSmithKline	Type 2 Diabetes Mellitus	February 2000	Not Applicable
NCT00314561	Korea University Anam Hospital	Metabolic Syndrome	May 2006	Phase 4
NCT00044460	GlaxoSmithKline	Diabetes Mellitus, Type 2	May 2002	Phase 4
NCT00522470	Baskent University	Type 2 Diabetes Mellitus\|Obesity		Phase 4
NCT00679939	GlaxoSmithKline	Diabetes Mellitus, Type 2	April 21, 2008	Phase 4
NCT00364221	University of Colorado, Denver	Metabolic Syndrome\|Insulin Resistance	November 2004	Phase 4
NCT00612066	Jonsson Comprehensive Cancer Center\|National Institutes of Health (NIH)	Cushing´s Disease	April 2007	Phase 2
NCT00541775	Merck Sharp & Dohme LLC	Type 2 Diabetes Mellitus	June 2006	Phase 3
NCT00615212	GlaxoSmithKline	Diabetes Mellitus, Type 2	January 2, 2008	Phase 1
NCT00264251	St. Luke´s-Roosevelt Hospital Center	HIV Infections\|Insulin Resistance\|Obesity	July 2005	Not Applicable
NCT01706211	National Taiwan University Hospital	Diabetes Mellitus Non Insulin Dependent Oral Agent Therapy	October 1998	Phase 3
NCT00306176	Aristotle University Of Thessaloniki\|University of Athens	Type II Diabetes Mellitus	January 2005	Phase 4
NCT00225355	University of Glasgow\|British Heart Foundation\|GlaxoSmithKline	Angina Pectoris\|Metabolic Syndrome X	February 2006	Phase 4
NCT00333151	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	May 2006	Phase 3
NCT00318422	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	May 2006	Phase 3
NCT02694874	Centro de Investigacao em Saude de Manhica\|University Health Network, Toronto\|Barcelona Institute for Global Health	Malaria	February 2016	Not Applicable
NCT00614874	Creighton University	Asthma	December 2008	Phase 2
NCT00285142	University Hospital, Montpellier	Healthy	June 2004	Not Applicable
NCT00422955	GlaxoSmithKline	Neuropathy, Diabetic	November 2003	Phase 3
NCT00285805	Radboud University Medical Center	Insulin Resistance	February 2006	Not Applicable
NCT00309309	Mario Negri Institute for Pharmacological Research	Kidney Transplant	April 2005	Phase 2
NCT00064727	National Heart, Lung, and Blood Institute (NHLBI)\|National Institutes of Health Clinical Center (CC)	Congestive Heart Failure	July 9, 2003	Phase 2
NCT00350779	Merck Sharp & Dohme LLC	Type 2 Diabetes Mellitus	June 12, 2006	Phase 3
NCT00511823	GlaxoSmithKline	Nausea and Vomiting, Chemotherapy-Induced	July 23, 2007	Phase 1
NCT00331487	Takeda\|Eli Lilly and Company	Diabetes Mellitus	September 2000	Phase 3
NCT01209143	Genentech, Inc.	Solid Cancers	November 2010	Phase 1
NCT03309319	Zhaoyun Zhang\|Huashan Hospital	Pituitary Tumor	October 16, 2016	Not Applicable
NCT00424762	University of Texas Southwestern Medical Center\|GlaxoSmithKline\|Biosite	Diabetes Mellitus, Type 2	February 2005	Phase 4
NCT00110851	Wellstat Therapeutics	Type 2 Diabetes Mellitus	April 2005	Phase 2
NCT00123643	St. Paul Heart Clinic\|GlaxoSmithKline	Type 2 Diabetes Mellitus	May 2003	Phase 4
NCT00337350	Massachusetts General Hospital\|National Alliance for Research on Schizophrenia and Depression\|Stanley Medical Research Institute	Schizophrenia	September 2003	Phase 4
NCT00333723	GlaxoSmithKline	Diabetes Mellitus, Type 2	July 28, 2000	Phase 4
NCT00306696	GlaxoSmithKline	Diabetes Mellitus	October 2002	Phase 4
NCT00095654	Gerstein, Hertzel, MD\|Canadian Institutes of Health Research (CIHR)\|Aventis Pharmaceuticals\|GlaxoSmithKline\|King Pharmaceuticals is now a wholly owned subsidiary of Pfizer\|Wyeth is now a wholly owned subsidiary of Pfizer	Impaired Glucose Tolerance\|Cardiovascular Disease\|Glucose Metabolism Disorders	July 2001	Phase 3
NCT00405015	Radboud University Medical Center\|GlaxoSmithKline	Ischemia-Reperfusion Injury\|The Metabolic Syndrome	April 2007	Phase 2
NCT00484419	Daiichi Sankyo, Inc.	Type 2 Diabetes\|Hyperlipidemia	May 2007	Phase 3
NCT00618072	New York Medical College\|Albert Einstein College of Medicine\|University of Tennessee	Hyperinsulinemia\|Insulin Resistance\|Obesity	January 2008	Phase 2
NCT00995995	GlaxoSmithKline	Diabetes Mellitus, Type 2	October 2008
NCT00256646	US Department of Veterans Affairs\|American Diabetes Association\|VA Office of Research and Development	Type 2 Diabetes Mellitus	June 2007
NCT00279045	GlaxoSmithKline	Diabetes Mellitus, Type 2	January 3, 2000	Phase 3
NCT00318630	GlaxoSmithKline	Asthma	July 22, 2005	Phase 1
NCT04114136	Dan Zandberg\|University of Pittsburgh	Melanoma\|NSCLC\|Hepatocellular Carcinoma\|Urothelial Cancer\|Gastric Adenocarcinoma\|HNSCC\|Esophageal Adenocarcinoma\|Microsatellite Instability-High Solid Malignant Tumor	September 14, 2020	Phase 2
NCT00065065	James Lewis\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|GlaxoSmithKline\|University of Pennsylvania	Ulcerative Colitis\|Inflammatory Bowel Disease	September 2002	Phase 2
NCT00098852	University of California, San Francisco\|National Cancer Institute (NCI)	Head and Neck Cancer	October 2004	Phase 2
NCT01332071	GlaxoSmithKline	Diabetes Mellitus, Type 2	November 24, 2009	Phase 1
NCT00015626	National Center for Research Resources (NCRR)	Insulin Resistance\|Diabetes Mellitus		Phase 2
NCT00015691	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections\|Lipodystrophy\|Hyperinsulinemia		Not Applicable
NCT00688207	GlaxoSmithKline	Alzheimer´s Disease	April 2008	Phase 1
NCT00609362	University of Aarhus	Change in Bone Mineral Density\|Change in Bone Marrow Fat Content	January 2008	Phase 2
NCT00240604	Hadassah Medical Organization	Glucose Intolerance	April 2005	Phase 3
NCT00358124	Sanofi	Type 2 Diabetes Mellitus	January 2001	Phase 4
NCT00399711	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	November 2006	Phase 3
NCT00242619	Stanford University	Depression\|Bipolar Disorder\|Insulin Resistance	July 2007	Not Applicable
NCT00081328	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Diabetes Mellitus, Type II	May 2004	Phase 3
NCT00373178	Aristotle University Of Thessaloniki\|University of Athens	Type 2 Diabetes Mellitus	January 2005	Phase 4
NCT00297063	GlaxoSmithKline	Diabetes Mellitus, Type 2	January 11, 2006	Phase 3
NCT00329225	GlaxoSmithKline	Diabetes Mellitus, Type 2	September 2002	Phase 4
NCT00115661	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|Berlex Foundation	Endometriosis	July 2005	Phase 2
NCT00372086	The University of New South Wales\|Sydney Children´s Hospitals Network\|National Health and Medical Research Council, Australia\|Novo Nordisk A+S	Type 1 Diabetes\|Puberty: >Tanner 2 Breast Development or Testis >4ml	August 2003	Phase 4
NCT00500955	GlaxoSmithKline	Diabetes Mellitus, Type 2	April 2000	Phase 3
NCT00207402	Brooke Army Medical Center\|InterMune	Hepatitis C	October 2005	Phase 4
NCT00465296	Medstar Health Research Institute\|GlaxoSmithKline	Metabolic Syndrome	January 2006	Phase 3
NCT00252499	US Department of Veterans Affairs\|VA Office of Research and Development	Fatty Liver\|Insulin Resistance	October 2005	Not Applicable
NCT01577095	China Medical University Hospital	Type 2 Diabetes Mellitus With Features of Insulin Resistance	April 2006	Phase 2
NCT00516880	Hospital Authority, Hong Kong	Chronic Disease\|Kidney Diseases\|Cardiovascular Diseases	March 2006	Not Applicable
NCT00819910	Ahmad Slim\|GlaxoSmithKline\|Brooke Army Medical Center	Hypertriglyceridemia in Type 4 Hyperlipidemia\|Non Diabetic Subjects With Normoglycemia	September 2008	Phase 4
NCT00121953	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Endometriosis	July 2005	Phase 2\|Phase 3
NCT00004180	Dana-Farber Cancer Institute\|National Cancer Institute (NCI)	Sarcoma	October 1999	Phase 2
NCT00381238	GlaxoSmithKline	Alzheimer´s Disease	June 20, 2006	Phase 2
NCT01195259	GlaxoSmithKline	Diabetes Mellitus, Type 2	October 2009
NCT00492700	Association pour la Recherche sur les Maladies Hépatiques Virales	Non Alcoholic Steatohepatitis	January 2003	Phase 2
NCT00409097	Amsterdam UMC, location VUmc	Critical Illness\|Multiple Organ Failure	April 2006	Phase 3
NCT00481429	Imperial College London\|GlaxoSmithKline	Diabetes Mellitus, Type 2	May 2007
NCT00140647	Gerstein, Hertzel, MD\|Heart and Stroke Foundation of Ontario	Atherosclerosis\|Impaired Glucose Tolerance\|Isolated Impaired Fasting Glucose\|Cardiovascular Disease	July 2001	Phase 3
NCT00501488	Central South University	Diabetes Mellitus	March 2006
NCT00154011	Technische Universität Dresden	Healthy Subjects	September 2005	Not Applicable
NCT00309660	Herlev Hospital	Ulcerative Colitis	November 2005	Phase 1\|Phase 2
NCT00018382	US Department of Veterans Affairs\|VA Office of Research and Development	Alzheimer Disease	October 1999	Phase 2
NCT00440375	Baskent University	Type 2 Diabetes Mellitus\|Obesity\|Menopause	June 2005	Phase 4
NCT00349427	GlaxoSmithKline	Type 2 Diabetes Mellitus\|Diabetes Mellitus, Type 2	October 2005	Phase 3
NCT00343980	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	October 10, 2006	Phase 3
NCT00428090	GlaxoSmithKline	Alzheimer´s Disease	February 27, 2007	Phase 3
NCT00675740	University of Leipzig	Impaired Glucose Tolerance	January 2004	Phase 4
NCT00169832	Laval University\|GlaxoSmithKline	Diabetes\|Coronary Artery Bypass Grafting	June 2003	Phase 3
NCT00231387	GlaxoSmithKline	Non-insulin-dependent Diabetes Mellitus	September 2002	Phase 3
NCT00348712	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	October 30, 2006	Phase 3
NCT00121966	Odense University Hospital	Type 2 Diabetes Mellitus	January 2003	Phase 4
NCT00025753	National Center for Research Resources (NCRR)\|The Campbell Foundation	HIV Infections\|Insulin Resistance		Not Applicable
NCT00733174	Denver Research Institute\|GlaxoSmithKline	Impaired Glucose Tolerance	March 2004	Phase 4
NCT00571506	University of Arkansas	Diabetes Mellitus, Type 2\|Vascular Diseases	May 2004	Phase 4
NCT00130286	Weill Medical College of Cornell University\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	HIV-Associated Lipodystrophy Syndrome\|Insulin Resistance\|HIV Infections\|Metabolic Syndrome X\|Body Weight Changes	March 2005	Phase 1\|Phase 2
NCT00413335	Yale University	Obesity\|Impaired Glucose Tolerance\|Type 2 Diabetes Mellitus	November 2005	Not Applicable
NCT00135330	AstraZeneca\|Eli Lilly and Company	Diabetes Mellitus, Type 2	October 2005	Phase 3
NCT00785213	Mutual Pharmaceutical Company, Inc.\|Cetero Research, San Antonio	Healthy	September 2008	Phase 1
NCT01332370	GlaxoSmithKline	Diabetes Mellitus, Type 2	December 2009
NCT00166803	National Taiwan University Hospital\|National Science Council, Taiwan	Diabetes Mellitus, Atherosclerosis	June 2005	Not Applicable
NCT00379600	GlaxoSmithKline	Arthritis, Rheumatoid	November 2004	Phase 2
NCT00551564	GlaxoSmithKline	Diabetes Mellitus, Type 2	July 31, 2007	Phase 1
NCT00432679	GlaxoSmithKline	Diabetes Mellitus, Type 2	May 24, 2006	Phase 3
NCT00466713	Stanford University	Dilated Cardiomyopathy	March 2007	Not Applicable
NCT00443170	GlaxoSmithKline	Healthy Subjects\|Anaemia	November 2006	Phase 1
NCT00274495	Beth Israel Medical Center	Chronic Hepatitis C Infection\|Fatty Liver	January 2006	Phase 4
NCT00265148	GlaxoSmithKline	Alzheimer´s Disease	May 18, 2004	Phase 2
NCT00523913	GlaxoSmithKline	Diabetes Mellitus, Type 2	November 2005	Phase 3
NCT00039663	National Institutes of Health Clinical Center (CC)	HIV Infections	May 2002	Phase 1
NCT00616642	Jonsson Comprehensive Cancer Center\|National Institutes of Health (NIH)	Brain and Central Nervous System Tumors	October 2006	Phase 2
NCT00304993	Foundation Research, Florida\|GlaxoSmithKline\|Kos Pharmaceuticals\|Abbott	Metabolic Syndrome X\|Insulin Resistance	January 2001	Phase 4
NCT00324675	Technische Universität Dresden	Type 2 Diabetes\|Overt Diabetic Nephropathy	August 2006	Not Applicable
NCT00367744	National Institute of Allergy and Infectious Diseases (NIAID)\|GlaxoSmithKline	HIV Infections	July 2006	Phase 2
NCT00178841	Vanderbilt University	Cutaneous T-cell Lymphoma\|Mycosis Fungoides\|Sezary Syndrome	June 2005	Phase 2
NCT00738023	Emory University\|GlaxoSmithKline	Type 2 Diabetes\|Hypertension	March 2004	Phase 4
NCT00032487	VA Office of Research and Development\|National Eye Institute (NEI)\|SmithKline Beecham	Type 2 Diabetes Mellitus	December 1, 2000	Phase 3
NCT00640224	Silva Arslanian\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|University of Pittsburgh	Polycystic Ovary Syndrome	March 2005	Phase 4
NCT01872780	Inje University	Healthy	August 2008	Phase 1
NCT00953498	Centre Hospitalier Universitaire Dijon	Type 2 Diabetes	October 2007	Phase 4
NCT00379769	GlaxoSmithKline	Diabetes Mellitus, Type 2	April 2001	Phase 3
NCT00348309	GlaxoSmithKline	Alzheimer´s Disease	July 6, 2006	Not Applicable
NCT01019356	Jean-Patrice Baillargeon\|Canadian Institutes of Health Research (CIHR)\|Université de Sherbrooke	Polycystic Ovary Syndrome	August 2006	Not Applicable
NCT00607945	Ohio State University\|National Center for Complementary and Integrative Health (NCCIH)\|GlaxoSmithKline\|Bunge Loders Croklaan\|LifeScan	Type 2 Diabetes Mellitus	January 2008	Phase 1
NCT00295633	AstraZeneca	Diabetes Mellitus, Type 2	March 2006	Phase 3
NCT00499707	GlaxoSmithKline	Diabetes Mellitus, Type 2	October 8, 2003	Phase 3
NCT01574820	National Cheng-Kung University Hospital	Prediabetes\|Coronary Artery Disease\|Insulin Resistance\|Glucose Intolerance	November 2006	Phase 3
NCT00123227	Royal Brompton & Harefield NHS Foundation Trust\|GlaxoSmithKline\|CORDA, The Heart Charity	Diabetes Mellitus, Type 2\|Vascular Diseases\|Hypertension	October 2002	Phase 3
NCT00452166	Leiden University Medical Center	Chronic Kidney Disease\|Insulin Resistance	April 2007	Phase 3
NCT01100619	Exelixis	Papillary Thyroid Cancer\|Follicular Thyroid Cancer\|Huerthle Cell Thyroid Cancer\|Renal Cell Carcinoma	April 2010	Phase 1
NCT00490568	GlaxoSmithKline	Alzheimer´s Disease	August 8, 2007	Phase 3
NCT00119496	University of Glasgow\|GlaxoSmithKline\|Chest, Heart and Stroke Association Scotland\|Chief Scientist Office of the Scottish Government	Asthma	July 2005	Phase 2\|Phase 3
NCT00232362	Texas Tech University Health Sciences Center	Type 2 Diabetes Mellitus	June 2007	Phase 1
NCT00348140	GlaxoSmithKline	Alzheimer´s Disease	July 12, 2006	Phase 3
NCT00550420	GlaxoSmithKline	Alzheimer´s Disease	October 1, 2007	Phase 3
NCT00282945	Pfizer	Type 2 Diabetes Mellitus	January 2006	Not Applicable
NCT00186537	Stanford University\|Abbott	Insulin Resistance\|Hypertriglyceridemia	September 2003	Not Applicable
NCT00427154	Novo Nordisk A+S	Diabetes\|Diabetes Mellitus, Type 2	January 10, 2007	Phase 3
NCT00334568	GlaxoSmithKline	Alzheimer´s Disease	December 2004	Phase 2
NCT00362726	Bristol-Myers Squibb	HIV Infections	September 2006	Phase 1
NCT00116831	GlaxoSmithKline	Atherosclerosis	January 2005	Phase 3
NCT02526615	Turku University Hospital\|SmithKline Beecham	Insulin Sensitivity\|Type 2 Diabetes	October 2000	Phase 4

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

-20°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 62.5 mg/mL ( 158.67 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.5388 mL	12.6939 mL	25.3878 mL
5 mM	0.5078 mL	2.5388 mL	5.0776 mL
10 mM	0.2539 mL	1.2694 mL	2.5388 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% Saline

Solubility: ≥ 10 mg/mL (25.39 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% Corn Oil

Solubility: 10 mg/mL (25.39 mM); Suspended solution; Need ultrasonic
3.

Add each solvent one by one: 10% DMSO >> 90% Saline

Solubility: ≥ 10 mg/mL (25.39 mM); Clear solution

* All of the co-solvents are available by MedChemExpress (MCE).